) pushed the Health Care sector lower today making it today's featured Health Care loser. The sector as a whole closed the day down 0.9%. By the end of trading, Gilead fell 86 cents (-1.7%) to $49.92 on light volume. Throughout the day, 4.9 million shares of Gilead exchanged hands as compared to its average daily volume of 6.8 million shares. The stock ranged in price between $49.84-$51.33 after having opened the day at $50.96 as compared to the previous trading day's close of $50.78. Other company's within the Health Care sector that declined today were:
), down 18.2%,
), down 17%,
), down 15%, and
), down 11.5%.
- ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases worldwide. Gilead has a market cap of $38.42 billion and is part of the
industry. The company has a P/E ratio of 15.3, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7. Shares are up 23.9% year to date as of the close of trading on Wednesday. Currently there are 18 analysts that rate Gilead a buy, no analysts rate it a sell, and five rate it a hold.
TheStreet Ratings rates Gilead as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income.
- You can view the full Gilead Ratings Report.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider
) while those bearish on the health care sector could consider
- Find other investment ideas from our top rated ETFs lists.